Abstract:The incidence and prevalence of drug-induced liver injury appear to be increasing globally, for example, with the introduction of checkpoint inhibitors. Several reviews have been published in the last decade on the epidemiology of DILI, both among hospitalized patients and in the general population, as well as from retrospective and prospective studies on DILI. Most of these reviews have not focused on newly recognized agents that have recently changed the landscape of DILI. Apart from liver injury associated with antibiotics, oncological agents, particularly checkpoint inhibitors, are increasingly being recognized as causing liver injury. The type of liver injury associated with these agents is not idiosyncratic but rather an indirect type of injury. Furthermore, recently, COVID-19 vaccines and green tea extract have been found to lead to liver injury. Checkpoint inhibitors have revolutionized the treatment of many malignancies, such as malignant melanoma, lung cancer, and renal cancer. Via the activation of T cells, they can increase immune activity against malignant cells, but at the same time, they can decrease immune tolerance and therefore lead to immune-related adverse effects in many organs. The most common adverse effect in clinical practice is liver injury. A recent prospective study demonstrated an 8% frequency of DILI due to the use of checkpoint inhibitors among patients with malignant melanoma and renal cancer. This rate is much higher than observed with drugs, leading to idiosyncratic liver injury. Shortly after the implementation of the worldwide vaccination program against COVID-19, several case reports were published on suspected vaccination-induced autoimmune-like hepatitis occurring shortly after the vaccination. At first, these reports were met with skepticism, but currently, around 100 reports have been published, and cases of positive recurrence have been reported. The clinical, biochemical, immunological, and histological features are indistinguishable from classic autoimmune hepatitis (AIH). These reactions are very similar to drug-induced autoimmune-like hepatitis (DI-ALH) due to drugs such as nitrofurantoin, minocycline, and infliximab, which do not relapse after a short course of corticosteroids, which is the general rule in classic autoimmune hepatitis (AIH). Green tea extract has been found to be a well-documented cause of acute hepatocellular liver injury with jaundice. A strong HLA association has been reported, showing a high prevalence of HLA-B*35:01 among patients suffering from green tea-induced liver injury. Overall, 3% of patients recruited in the DILIN study were supplemented with green tea extract as one of the ingredients. In a prospective population-based study from Iceland, green tea was implicated in approximately 8% of patients with DILI.

[Drug-induced autoimmune-like liver injury]

Idiosyncratic drug-induced liver injury: an overview

Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury

Dissecting the molecular pathophysiology of drug-induced liver injury

The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update

Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Drug-induced liver injury: a comprehensive review

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use

Features of Autoimmune Hepatitis in Patients with Drug-induced Liver Injury

Metabolomic profiling for drug-induced liver injury with autoantibodies

[Research Progress on Laboratory Diagnosis of Drug-Induced Liver Injury].

Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury

Clinical and histopathologic features of drug-induced autoimmune hepatitis

Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

S4427 Drug-Induced Autoimmune-Like Hepatitis and Stevens Johnsons Syndrome Secondary to Levetiracetam